Objective:The purpose of ths study was to evaluate the expression of a novel autologous ovarian tumor-associated antigen in eight human ovarian tumor cell lines compared with other ovarian tumor markers and products of oncogenes.
Methods:Autologous antibodies were eluted from human ovarian tumor-membrane fragments purified in our laboratory. These antibodies react with autologous ovarian tumor-associated antigens (AOTA) and have a high degree of specificity for human ovarian tumors. They do not bind to normal ovarian or nonovarian tissue, or to nonovarian neoplastic tissues. We evaluated eight human ovarian adenocarcinoma cell lines (2008, 2774, Caov-3, OVCAR-3, PA-1, SW 626, UCI 101, and UCI 107) by indirect immunofluorescence to determine the expression of AOTA relative to the ovarian cancer tumor marker CA 125 and the products of selected oncogenes (p53, c-neu, and c-myc).
Results:The patterns and intensities of immunofluorescence correlated most closely between AOTA and c-neu. For example, AOTA and c-neu wete detected in all eight cell lines and displayed very strong cytoplasmic fluorescence on cell lines 2774, UCI 101, and UCI 107, CA 125 was present in the cytoplasm of four of eight cell lines. A tumor suppressor gene product, p53, exhibited a nuclear staining pattern in six of eight cell lines.
Conclusions:These data suggest that AOTA and the products of the c-neu oncogene may share certain epitopes. Current studies are undenvay to increase our understanding of the humoral response to ovarian cancer and the possible relationship to the expression of tumor oncogene products. Further characterization of AOTA will be necessary before early diagnostic texts can be developed.
1. Wingo PA, Tong T, Bolden S. Cancer Statistics, 1995. CA1995;45:8-30.
2.
2. Herbst AL. The epidemiology of ovarian cancer and the current status of tumor markers to detect disease. Am J Obstet Gynecol1994;170:1099-1107.
3.
3. Urban JL, Schreiber H. Tumor antigens. Ann Rev Immunol1992;10:617-644.
4.
4. McKenzie SJ, DeSombre KA, Bast BS, et al. Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185 neu in human ovarian cancer. Cancer1993;71:3942-3946.
6. Berchuck A. Kohler MF, Marks JR, Wiseman R, Boyd J, Bast R.C. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol1994;170:246-252.
7.
7. Bast RC, Fenney M, Lazarus H. Reactivity o a monoclonal antibody with human ovarian cancer. J Clin Invest1981;68:1331-1337.
8.
8. Dawson JR, Kutteh WH, Whitesides DB, Gall SA. Identification of tumor-associated antigens and their purification from cyst fluids from ovarian and epithelial neoplasms. Gynecol Oncol1980;10:6-17.
9.
9. Knauf S, Urbach GI. A study of ovarian cancer patients using a radioimmunoassay for human ovarian tumor-associated antigen OCA. Am J Obstet Gynecol1980;138:1222-1223.
10.
10. Bhattacharya M, Chatterjee SK, Barlow JJ, et al. Monoclonal antibodies recognizing tumor-associated antigen of human ovarian mucinous cystadenocarcinomas. Cancer Res1982;42:1650-1654.
11.
11. Kutteh WH, Welander CE, Homesley HD, Doellgast GF. Autologous antibodies eluted from membrane fragments isolated from the effusions of human ovarian epithelial neoplasia. I. Quantitation of antibodies. Am J Obstet Gynecol1985;153:124-129.
12.
12. Kutteh WH, Doellgast GJ. Autologous antibodies eluded from membrane fragments in human ovarian epithelial neoplastic effusions. II. Tissue specificity and reactivity. J Nat Cancer Inst1986;76:797-804.
13.
13. Kutteh WH, Baker VV. Doellgast GJ. Autologous antibodies eluted from membrane fragments in human ovarian epithelial neoplastic effusions. III. Cytotoxic potential in vitro and characterization of antigen(s). Am J Obstet Gynecol1990;163:1301-1306.
14.
14. Giancotti FR, Dorsett BH, Qian H, Cronin WJ, Barber HRK, Ioachim HL. Ovarian cancer-associated antibodies recovered from ascites: Their use for the isolation of ovarian cancer-associated antigen to produce monoclonal antibodies. Gynecol Oncol1990;37:24-28.
15.
15. Lutz PM, Dawson J. Activity of antibodies recovered from immune complexes of ovarian cancer patients. Cancer Immunother1984;17:180-189.
16.
16. Stomayor EM, Fu Y-X, Lopez-Cepero M, et al. Role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocracinoma. II. Down-regulation of macrophage-mediated cytotoxicity by tumor-derived granulocyte-macrophage colony-stimulating factor. J Immunol1991;147:2816-2823.
17.
17. Black PH. Shedding from the cell surface of normal and cancer cells. Adv Cancer Res1980;32:75-199.
18.
18. Courtenay-Luck NS, Epenetos AA, Sivolapenko GB, Larche M, Barkans JR, Ritter MA. Development of anti-idiotypic antibodies against tumor antigens and autoantigens in ovarian carrier patients treated intraperitoneally with most monoclonal antibodies. Lancet1988;ii:894-896.
19.
19. Subba-Rao G, Hanjani P. Detection of human tumor-associated antigens by antibodies isolated from ovarian carcinoma ascitc fluid. Am J Obstet Gynecol1988;159:94-98.
20.
20. Meden H, Marx D, Fattahi A, et al. Elevated serum levels of a C-erbB-2 oncogene product in ovarian cancer patients and in pregnancy. J Cancer Res Clin Oncol1994;120:378-381.
21.
21. Yaginuma Y, Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res1992;52:4196-4199.
22.
22. Bast RC, Boyer CM, Jacobs I, et al. Cell growth regulation in epithelial ovarian cancer. Cancer1993;74:1597-1601.
23.
23. Rubin SC, Finstad CL, Federici MG, Scheiner L, Lloyd KO, Hoskins WJ. Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. Cancer1994;73:1456-1459.
24.
24. Katsaros D, Theillet C, Zola P, et al. Concurrent abnormal expression of erbB-2, myc, and ras genes is associated with poor outcome of ovarian cancer patients. Anticancer Res1995;15:1501-1510.
